Research graph
References from Temporal trends and regional disparities in costs and affordability of non-insulin antidiabetic drugs in China, 2015–2022: a retrospective observational study. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
National Primary Diabetes Control Management Manual (2022)
2022 · External reference
A systematic review of the economic burden of diabetes mellitus: contrasting perspectives from high and low middle-income countries
10.1080/20523211.2024.2322107 · 2024 · External reference
How Serious is the Economic Burden of Diabetes Mellitus in Hainan Province? A Study Based on “System of Health Account 2011”
10.1007/s13300-019-00712-0 · 2019 · External reference
Unresolved reference
External reference
Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review
10.1186/s12913-018-3772-8 · 2018 · External reference
Economic burden and medication use among elderly patients with diabetes in Beijing, China: An analysis based on electronic medical insurance data
10.3389/fphar.2025.1549244 · 2025 · External reference
10.21203/rs.3.rs-3930430/v1
10.21203/rs.3.rs-3930430/v1 · External reference
Analysis of Impact of Volume-based Procurement Policy on Use of Oral Hypoglycemic Drugs
2023 · External reference
Analysis of the use of oral hypoglycemic drugs in a certain hospital under the background of national centralized procurement
2024 · External reference
Impact of volume-based procurement on the use of original and generic oral hypoglycemic drugs in a hospital
2024 · External reference
National Volume-Based Procurement (NVBP) exclusively for insulin: towards affordable access in China and beyond
10.1136/bmjgh-2023-014489 · 2024 · External reference
Analysing the effects of National Centralised Drug Procurement and Price Negotiation Policies on novel hypoglycaemic drug usage and costs in Shanghai, China: an interrupted time series analysis
10.1136/bmjopen-2024-088318 · 2024 · External reference
Trends in antidiabetic drug use and expenditure in public hospitals in Northwest China, 2012-21: a case study of Gansu Province
10.1186/s12913-024-10917-0 · 2024 · External reference
Unresolved reference
External reference
Chinese Diabetes Society. Guideline for the prevention and treatment of diabetes mellitus in China
2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Impacts of China’s National Volume-Based Procurement policy on the pharmaceutical industry: A systematic review
10.1016/j.pharp.2025.06.003 · 2025 · External reference
Unresolved reference
External reference
The Impact of the Consistency Evaluation Policy of Generic Drugs on R&D Investment Intensity of Pharmaceutical Companies-An Empirical Study Based on the Difference-in-Differences Model
10.3389/fpubh.2022.902025 · 2022 · External reference
Analysis on the Use of Hypoglycemic Drug in T2DM with High ASCVD Risk in 22 Hospitals in Beijing
2023 · External reference
The price and affordability of essential medicines, progress and regional distribution in China: a systematic review
10.3389/fphar.2023.1153972 · 2023 · External reference
Improving access to medicines and beyond: the national volume-based procurement policy in China
10.1136/bmjgh-2022-011535 · 2023 · External reference
Factors Impacting Pharmaceutical Prices and Affordability: Narrative Review
10.3390/pharmacy9010001 · 2021 · External reference
Survey on the Utilization of Dipeptidyl Peptidase IV Inhibitors and Glucagon-like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter Protein 2 Inhibitors in Seven Cities in China, 2014-2018
2020 · External reference
